IL319413A - Adjunctive dosing and administration of anti-C5 antibodies for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). - Google Patents

Adjunctive dosing and administration of anti-C5 antibodies for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA).

Info

Publication number
IL319413A
IL319413A IL319413A IL31941325A IL319413A IL 319413 A IL319413 A IL 319413A IL 319413 A IL319413 A IL 319413A IL 31941325 A IL31941325 A IL 31941325A IL 319413 A IL319413 A IL 319413A
Authority
IL
Israel
Prior art keywords
hsct
tma
antibodies
administration
stem cell
Prior art date
Application number
IL319413A
Other languages
English (en)
Hebrew (he)
Inventor
Stephan Ortiz
Jonathan Monteleone
Xiaofeng Wang Rears
Original Assignee
Alexion Pharma Inc
Stephan Ortiz
Jonathan Monteleone
Xiaofeng Wang Rears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc, Stephan Ortiz, Jonathan Monteleone, Xiaofeng Wang Rears filed Critical Alexion Pharma Inc
Publication of IL319413A publication Critical patent/IL319413A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL319413A 2022-09-06 2023-09-01 Adjunctive dosing and administration of anti-C5 antibodies for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). IL319413A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263404061P 2022-09-06 2022-09-06
US202363440984P 2023-01-25 2023-01-25
PCT/US2023/031836 WO2024054408A1 (en) 2022-09-06 2023-09-01 Supplemental dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)

Publications (1)

Publication Number Publication Date
IL319413A true IL319413A (en) 2025-05-01

Family

ID=88192212

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319413A IL319413A (en) 2022-09-06 2023-09-01 Adjunctive dosing and administration of anti-C5 antibodies for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA).

Country Status (9)

Country Link
EP (1) EP4583910A1 (de)
JP (1) JP2025529317A (de)
KR (1) KR20250060282A (de)
CN (1) CN120076827A (de)
AU (1) AU2023338677A1 (de)
CA (1) CA3266974A1 (de)
IL (1) IL319413A (de)
TW (1) TW202426048A (de)
WO (1) WO2024054408A1 (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
JP6654137B2 (ja) * 2013-09-16 2020-02-26 チルドレンズ ホスピタル メディカル センター Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
US11840564B2 (en) * 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
TW201718014A (zh) * 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
US20220370556A1 (en) * 2019-09-27 2022-11-24 Volution Immuno Pharmaceuticals Sa Method of Treatment
WO2022036151A1 (en) 2020-08-13 2022-02-17 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
EP4281472A1 (de) * 2021-01-22 2023-11-29 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von komplementvermittelter thrombotischer mikroangiopathie unter verwendung eines anti-c5-antikörpers

Also Published As

Publication number Publication date
EP4583910A1 (de) 2025-07-16
KR20250060282A (ko) 2025-05-07
WO2024054408A1 (en) 2024-03-14
AU2023338677A1 (en) 2025-03-27
TW202426048A (zh) 2024-07-01
CA3266974A1 (en) 2024-03-14
JP2025529317A (ja) 2025-09-04
CN120076827A (zh) 2025-05-30

Similar Documents

Publication Publication Date Title
IL300115A (en) Dosage and Administration of ANTI-C5 Antibodies for Hematopoietic Stem Cell Transplantation Treatment (HSCT-TMA)
IL319413A (en) Adjunctive dosing and administration of anti-C5 antibodies for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA).
EP4063498C0 (de) Oxa-23-typ carbapenemase-resistente hybridoma-zelllinie und verwendung von monoklonalen antikörpern (mab) davon
SI4121007T1 (sl) Formulacije protiteles proti amiloidnemu beta peptidnemu protofibrilu z visoko koncentracijo in načini njihove uporabe
Sanghani-Kerai et al. Osteoporosis and ageing affects the migration of stem cells and this is ameliorated by transfection with CXCR4
HK40088954A (en) Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
MX2022005249A (es) Anticuerpos anti-cd45 y conjugados de los mismos.
IL304593A (en) Methods for the treatment of complement-mediated thrombotic microangiopathy using an anti-c5 antibody
IL319674A (en) Human anti-IL-1R3 antibody and methods of use
IL315845A (en) Anti-dectin-1 antibodies and methods of using them
IL317133A (en) Methods and systems for cell differentiation using optogenetics
IL314656A (en) A component for a transfer system and a method and device for producing a component for a transfer system
Studentsov et al. Adaptogens and related groups of drugs-50 years of searching
IL318694A (en) Antibodies against CCR8 and methods of using them
IL317690A (en) Anti-GPNMB antibodies and methods of using them
IL318036A (en) Bispecific anti-PCRV and PSL antibodies for the treatment of bronchiectasis
IL317698A (en) Methods and compositions for stem cell differentiation
WO2023192321A3 (en) Genetically engineered antibody resistant (gear) cells for adoptive cellular therapy
WO2023133296A3 (en) Engineered pd-l1-targeting gamma delta t cell receptors
Kints et al. Rat monoclonal antibodies VII. Enhancement of ascites production and yield of monoclonal antibodies in rats following pretreatment with pristane and Freund's adjuvant
IL316326A (en) Antibody that binds to VEGF-A and IL6 and methods of use
De Boer et al. Requirements for the generation of memory B cells in vivo and their subsequent activation in vitro for the production of antigen-specific hybridomas
GB202408901D0 (en) Antibodies and methods of treatment
IL320671A (en) Anti-FGFR3 Antibodies and Antigen-Binding Fragments and Methods of Using Them
EA202090696A1 (ru) Комбинированная терапия рака поджелудочной железы комбинацией анти-csf1r и анти-pd-1 антител